This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers, clinicians and innovators. The series will help attendees anticipate, access, and apply new approaches and technologies for patient care.
The Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
We are pleased to share that as of the 2026/2027 season, the Garrod Association will be providing two presentations per season.
To register, click the button below or go to: https://us06web.zoom.us/webinar/register/WN_e2yO6xnsSK2v70BLslqwjA
2025-2026 Leading Strand from 12:00pm – 1:00pm ET on:
Friday January 30, 2026
Canadian Guidelines for the Management of Spinal Bulbar Muscular Atrophy
Review the high prevalence of SBMA in Indigenous people in Canada, and the need for increased awareness. Discuss the process and content of the recently published Canadian SBMA guideline.
Learning Objectives:
- Discuss the need for the recently published Canadian guidelines.
- Recognize the significance of Spinal Bulbar Muscular Atrophy for Indigenous people in Canada.
- Understand what the new SBMA Guidelines mean for health care professionals.
- Discuss ongoing endeavors to promote awareness of SBMA guidelines.
Speaker: Dr. Kerri Schellenberg
Dr. Kerri Schellenberg, MD, FRCPC, MMedEd is a Neuromuscular Neurologist and Associate Professor at the University of Saskatchewan. She is the Medical Director of the ALS/MND clinic and the Medical Director of the Royal University Hospital EMG lab. She serves as Competency Committee Chair for the neurology program. Her research primarily focuses on motor neuron diseases (ALS, SBMA, and SMA), and includes publications in clinical aspects of neuromuscular disease. She has served as local PI for international treatment trials in ALS, local PI for the Canadian Neuromuscular Disease registry, contributed to Canadian ALS Best Practice Recommendations, and has ongoing grants and projects with local and national research partners to further understanding of neuromuscular disease.
She completed her medical studies at the University of Saskatchewan, a Neurology residency at the University of Alberta, followed by a Neuromuscular fellowship at Duke University in North Carolina. Dr. Schellenberg was the recipient of the Betty Norman Research Fellowship Award from the ALS Society of Canada to pursue an ALS fellowship at the University of Alberta. She has a Masters of Medical Education from the University of Dundee.
